Biotech Values

[DewDiligence]

Re: EPIX

>Another possibility is that the agency has an ax to grind with Epix or their partner Schering for some reason, or perhaps the FDA fears that the widespread use of enhanced MRA will help further bankrupt the Medicare system cost-wise.<

MRA’s ought to be cheaper than angiography and hence, unless doctors were ordering them willy-nilly (which wouldn’t be covered by anyone), MRA’s could potentially lower healthcare costs.

>Either way, Epix is getting the shaft big time…<

It would appear so.